X0306 4 2022-03-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001268304 IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2022-03-01 4 M 0 688 A 264662 D Common Stock 2022-03-02 4 S 0 354 1.866 D 264308 D Common Stock 2022-03-01 4 M 0 20250 A 284558 D Common Stock 2022-03-02 4 S 0 10416 1.866 D 274142 D Restricted Stock Units 2022-03-01 4 A 0 81000 0.00 A Common Stock 81000 81000 D Restricted Stock Units 2022-03-01 4 M 0 20250 0.00 A Common Stock 20250 60750 D Restricted Stock Units 2022-03-01 4 M 0 688 0.00 A Common Stock 688 0 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $1.863 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The Restricted Stock Units shall vest as to 25% of the units on March 1, 2023, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Executive Vice President of Technical Operations and Chief Regulatory Officer /s/ Gillian Ivers-Read 2022-03-02